As if that's not bad enough, the operating revenue also dropped by 11%, making us very wary indeed. One thing for shareholders to keep front in mind is that Harpoon Therapeutics increased its cash burn by 1,207% in the last twelve months.
NasdaqGS:HARP Debt to Equity History July 30th 2022 How Well Is Harpoon Therapeutics Growing? The image below shows how its cash balance has been changing over the last few years. That's quite a short cash runway, indicating the company must either reduce its annual cash burn or replenish its cash. That means it had a cash runway of around 10 months as of March 2022. Looking at the last year, the company burnt through US$129m. When Harpoon Therapeutics last reported its balance sheet in March 2022, it had zero debt and cash worth US$112m. View our latest analysis for Harpoon Therapeutics Does Harpoon Therapeutics Have A Long Cash Runway?Ī company's cash runway is calculated by dividing its cash hoard by its cash burn. Let's start with an examination of the business' cash, relative to its cash burn.
#Harpoon therapeutics stock free
In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. So, the natural question for Harpoon Therapeutics ( NASDAQ:HARP) shareholders is whether they should be concerned by its rate of cash burn. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. For example, although software-as-a-service business lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed.
Just because a business does not make any money, does not mean that the stock will go down.
0 kommentar(er)
